Abstract
Aiming at the development of anticancer agents by modification of phenolic benzo[c]phenanthridine alkaloid, additional hydroxyl group was put on C10 position of fagaridine (1) by a biomimetic synthetic procedure to afford 10-hydroxyfagaridine (12). All of the synthetic intermediates were also screenedin vitro antitumor activities against five different cell lines as well as12. Among them the representative cytotoxic results are shown as follows;p-quinone (11) [ED50 (A549=0.22 μg/ml), (HCT15=0.21 μg/ml), fagaridine (1) (HCT 15=0.41 μg/ml), olefin (6) (HCT 15=0.06 μg/ml), acetal (7) (SKMEL-2=0.07 μg/ml), dihydrofagaridne (10) (A549=0. 38 μg/ml), 10-hydroxyfagaridine (12) (A 549=0.45 μg/ml). From these observation three main remarks can be drawn; (i) the iminium part of benzo[c]phenanthridine is not essential for showing acitvities, (ii) the additional hydroxyl group did not contribute to enhance the cytotoxicity, (iii) the 3-arylisoquinolin-1(2H)-one derivatives were found to display significantin vitro antitumor activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Cho, W. J., and Hanaoka, M., A First Synthesis of Isofagaridine: Topoisomerase I Inhibitor,Arch. Pharm. Res., 19, 240–242 (1996).
Cushman, M., Moham, P., Synthesis and Antitumor Activity of Structural Analogues of the Anticancer Benzophenanthridine Alkaloid Fagaronine Chloride,J. Med. Chem., 28, 1031–1036 (1985).
Hanaoka, M. and Mukai C., “Studies in Natural Products Chemistry” Vol 14, Rahman A-u., (Eds.), Elsevier, 1994, pp 769–803.
Hanaoka, M., Motonishi T., and Mukai C., A Biomimetic Synthesis of Oxychelerythrine, Dihydrochelerythrine, and Chelerythrine from Berberine,J. Chem. Soc. Perkin Trans. 1, 2253–2256 (1986).
Hanaoka, M., Yamagishi H., and Mukai C., Synthesis of Fagaridine, A Phenolic Benzo[c]phenanthridine Alkaloids,Chem. Pharm. Bull., 33, 1763–1765 (1985).
Hanaoka, M., Cho, W. J., Yoshida, S., and Mukai, C., Biomimetic Introduction of Oxy Functionality at the C10 Position in the Benzo[c]phenanthridine Skeleton: Synthesis of 2,3,7,8,10- Pentaoxygenated Benzo[c]phenanthridine Alkaloids, Chelilutine and Sanguilutine,Chem. Pharm. Bull., 39, 1163–1166 (1991).
Fang, S.-D., Wang, L.-K. and Hecht, S. M., Inhibitors of DNA Topoisomerase I Isolated from the Roots ofZanthoxylum nitidum, J. Org. Chem., 58, 5025–5027 (1993).
Janain, Y. L., Croisy, A., Riou, J.-F., and Bisagni, E., Synthesis and Evaluation of New 6-Amino-substututed Benzo[c]phenanthridine Derivatives,J. Med. Chem., 36, 3686–3692 (1993).
Kobayashi, F., Yokumoto, H., Suzuki, M. and Tsubaki, M.,Chem. Abstr., 1993, 118, 219845,
Onda, M., and Yamaguchi, H., Utilization of Protopine and Related Alkaloids. XI.,Chem. Pharm. Bull., 27, 2076–2083 (1979).
Onda, M., and Yonezawa, K., and Abe, K., Transformation of Protopine and Protoberberine Alkaloid to Benzo[c]phenanthridine AlkaloidChem. Pharm. Bull., 19, 31 (1971).
Rubinstein, L. V., Shoemaker, R. H., Paul, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D., Monks, A., and Boyd, M. R.,J. Natl, Cancer Inst., 82, 1113 (1990).
Simeon, S., Rios, J. L., Villar, A., Pharmacological Activity of Benzophenanthridine and Phenanthridine Alkaloids,Pharmazie, 44, 593–597 (1989).
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J. B., Vistica, D. T., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R.,J. Natl. Cancer Inst., 82, 1107 (1990).
Sufness, M., Douros, J., In Methods in Cancer Research, De Vita, V. T., Jr., Busch, H., (Eds.), Academic Press: New York, 1979, pp. 474.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cho, WJ., Yoo, SJ., Chung, BH. et al. Synthesis of benzo[c]phenanthridine derivatives and theirin vitro antitumor activities. Arch. Pharm. Res. 19, 321–325 (1996). https://doi.org/10.1007/BF02976249
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976249